| Revenue | 29.05a | 32.71a | 31.53a |
| Operating expenses | — | — | — |
| Cost of revenues | -0.91a | -1.6a | -3.03a |
| Research and development | -550.41a | -439.91a | -454.06a |
| Acquired in-process research and development | | -26.45a | -97.75a |
| General and administrative | -591.41a | -416.13a | -383.45a |
| Total operating expenses | -1,142.73a | -884.09a | -938.29a |
| Gain on sale of Telavant net assets | 110.39a | 5,348.41a | |
| (Loss) income from operations | -1,003.29a | 4,497.03a | -906.76a |
| Change in fair value of investments | -55.19a | 47.97a | 20.82a |
| Change in fair value of liability instruments | -15.76a | 46.84a | 18.39a |
| Gain on deconsolidation of subsidiaries | -3.11a | -32.77a | -29.28a |
| Interest income | -258.38a | -146.43a | -32.18a |
| Other expense, net | 10.72a | 13.56a | 0.49a |
| (Loss) income from continuing operations before income taxes | -681.59a | 4,567.86a | -884.99a |
| Income tax expense | -48.17a | -21.5a | -4.08a |
| (Loss) income from continuing operations, net of tax | -729.76a | 4,546.35a | -889.07a |
| Income (loss) from discontinued operations, net of tax | 373.03a | -315.15a | -226.39a |
| Net (loss) income | -356.73a | 4,231.21a | -1,115.46a |
| Net loss attributable to noncontrolling interests | -184.75a | -117.72a | -106.43a |
| Net (loss) income attributable to Roivant Sciences Ltd. | -171.98a | 4,348.93a | -1,009.03a |
| Amounts attributable to Roivant Sciences Ltd. | — | — | — |
| (Loss) income from continuing operations, net of tax | -545.17a | 4,662.7a | -784.35a |
| Income (loss) from discontinued operations, net of tax | 373.19a | -313.78a | -224.68a |
| Net (loss) income attributable to Roivant Sciences Ltd. | -171.98a | 4,348.93a | -1,009.03a |